Table 3. The pharmacokinetic parameters of crizotinib and 2-keto crizotinib in rats (n = 5, mean ± S.D.).

Compound	Crizotinib		2-Keto crizotinib
Group	Crizotinib	Crizotinib + Tropifexor	Crizotinib	Crizotinib + Tropifexor
AUC(0−t)(ng/mL*h)	4,098.16 ± 480.24	5,563.04 ± 1,112.56*	603.21 ± 97.71	877.14 ± 268.34
AUC(0−∞) (ng/mL*h)	4,141.79 ± 490.95	5,669.41 ± 1,166.99*	604.85 ± 99.06	879.58 ± 268.53
t1/2 (h)	6.83 ± 0.77	8.23 ± 1.65	4.82 ± 1.18	5.78 ± 1.79
Tmax (h)	8.80 ± 1.79	8.80 ± 1.79	8.00 ± 0.00	8.80 ± 1.79
CLz/F (L/h/kg)	6.10 ± 0.69	4.56 ± 0.90*	42.25 ± 7.06	30.44 ± 8.32*
Cmax (ng/mL)	236.97 ± 45.30	325.92 ± 40.95*	51.05 ± 14.39	74.33 ± 26.83

Notes.

Significant differences from control group, *P < 0.05.